Cystic Fibrosis: Pancreatic Enzyme Replacement Therapy
The question
To ask the Secretary of State for Health and Social Care, what steps he is taking to protect patients with cystic fibrosis in the context of a shortage of Creon gastro-resistant capsules.
Answered by Karin Smyth
The Department is in regular discussions with the supplier of Creon on the latest stock availability and the actions that are being taken to mitigate the supply issue that is affecting the whole of the United Kingdom. Through these discussions we have managed to secure additional volumes of Creon for 2025 for the UK. We are continuing to work with all suppliers of pancreatic enzyme replacement therapy (PERT) to understand what more can be done to add further resilience to the market. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market.
In the longer term, the Department has had interest from non-UK suppliers of PERT wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency (MHRA), we are working with these potential suppliers, and if authorised, these products could further diversify and strengthen the market.
The Department has issued management advice to healthcare professionals which directs clinicians to unlicensed imports when licensed stock is unavailable, and which includes actions for integrated care boards to put in place local mitigation plans to ensure that patients are not left without PERT. The Department, in collaboration with NHS England, has created a public facing page to include the latest update on PERT availability and easily accessible prescribing advice for clinicians.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →